The role of surgery in the management of solitary pulmonary nodule in breast cancer patients

Rena, Ottavio; Papalia, Esther; Ruffini, Enrico; Filosso, Pier Luigi; Oliaro, A; Maggi, G; Casadio, Caterina

doi:10.1016/j.ejso.2006.12.015

Cited by 70 publications

(76 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten of the reviewed studies were case series, together reporting on over 971 patients with treated breast carcinoma and pulmonary metastasectomy [2][3][4][5][6][7][8][9][10][11]. Operations were performed between 1960 and 2007.…”

Section: Methodsmentioning

confidence: 99%

“…The literature search performed on 15 February 2017 had 2426 hits in MEDLINE and found one review article in the Cochrane library. After step-wise appraisal 11 studies where identified each with at least 20 patients having had lung metastasectomy following primary tumour treatment with curative intent [2][3][4][5][6][7][8][9][10][11][12].…”

Section: Methodsmentioning

confidence: 99%

“…For this prognostic factor results were heterogeneous between the studies analysed: six studies found a statistically significant influence on post-metastasectomy survival for this parameter while four author groups found no evidence for a significant influence on prognosis. Despite shortened disease-free intervals of below 36 months patients achieved a median survival of 28.8 to 34.4 months and five-year survival rates of 21 to 33.3 % following lung metastasis surgery [4,6,7,9]. Complete resectability of all lung lesions is considered to be the most important indication criterion for lung metastasis of surgery.…”

Section: Prognostic Factors For Survival After Metastasis Surgerymentioning

confidence: 99%

“…Pulmonary metastasectomy resulted in a median post-metastasectomy survival of 32 to 96.6 months (▶ Table 2) [2][3][4][5][8][9][10][11]. Five-year survival rates were between 30.8 and 54.4 %, while 10-year survival rates were between 18 and 51 % [2][3][4][5][6][7][8][9][10]. One meta-analysis from the year 2015 analysed the survival prognosis of patients with breast carcinoma after lung metastasis surgery quantitatively [12].…”

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

“…Prognostic factors (based on univariate analyses) Friedel et al [2] Ludwig et al [3] Planchard et al [4] Tanaka et al [5] Rena et al [6] Chen et al [7] Welter et al [8] Kycler et al [9] Yoshimoto et al [10] Meimarakis et al [ …”

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 99%

See 4 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

ABSTR AC TBreast carcinoma with pulmonary metastasis can be treated locally or systemically. Following primary tumour resection patients with isolated, completely resectable pulmonary nodules and definite functional operability can be offered lung metastasis resection. Following metastasectomy a median survival of 32 to 96.6 months can be achieved with corresponding five-year survival rates between 30.8 and 54.4 %. The procedure is associated with a mortality rate of 0 to 3 %. The most important independent prognostic factor for longterm survival is complete resection of all lung lesions. The configuration and pattern of metastasis as well as disease-free interval, hormone and HER2/neu receptor status also appear to influence prognosis, but are of lesser importance. Intrapulmonary recurrence of metastases may, after careful selection on a case-by-case basis, also be treated operatively. In some cases this is associated with a favourable long-term prognosis. Pulmonary metastasectomy should be the treatment of choice for selected patients with metastatic breast carcinoma. ZUSAMMENFASSUNG

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Prognostic Factors For Survival After Metastasis Surgerymentioning

confidence: 99%

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 99%

See 3 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy

Yhim

Han

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy. METH-ODS: The authors consecutively enrolled 140 recurrent breast cancer patients with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital and retrospectively analyzed 45 patients who had <4 metastatic lesions. RESULTS: Fifteen patients had pulmonary metastasectomy followed by systemic treatment (pulmonary metastasectomy group), and 30 received systemic treatment alone (nonpulmonary metastasectomy group). The 3-year progression-free survival (PFS) and 4-year overall survival (OS) was significantly longer in the pulmonary metastasectomy group than in the nonpulmonary metastasectomy group (3-year PFS, 55.0% vs 4.5%, P < .001; 4-year OS, 82.1% vs 31.6%, P ¼ .001). In multivariate analysis, a disease-free interval (DFI) of <24 months (hazard ratio [HR], 4.53; 95% CI, 1.72-11.90), no pulmonary metastasectomy (HR, 9.52; 95% CI, 3.34-27.18) and biologic subtypes such as human epithelial growth factor receptor-2 positive (HR, 3.00; 95% CI, 1.04-8.64) and triple negative (HR, 3.92; 95% CI, 1.32-11.59) were independent prognostic factors for shorter PFS. CONCLUSIONS: The authors' results demonstrated that DFI and biologic subtypes of tumor are firm, independent, prognostic factors for survival, and pulmonary metastasectomy can be a reasonable treatment option in this population. Further prospective studies are warranted to evaluate the role of pulmonary metastasectomy. Cancer 2010;116:2890-901.

show abstract